Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEAKTransplant: Dapagliflozin in Transplanted Kidneys
NCT05788276Phase 4Active, not recruiting
- Sponsor
- Oslo University Hospital
- Start
- May 2023
- Primary completion
- Aug 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of dapagliflozin in Kidney Transplant Failure (KTF) and kidney failure (ESRD) (2 arms), sponsored by Oslo University Hospital. Primary endpoint: Glomerular Filtration Rate slope at 3 years. Started May 2023; status: active, not recruiting.
02
Drugs
dapagliflozin
03
Conditions
Kidney Transplant Failure (KTF)kidney failure (ESRD)
Beyond the preview
Go deeper on NCT05788276.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05788276.